Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

WGS Implementation in standard cancer Diagnostics for Every cancer patient (WIDE)

Date

30 Sep 2019

Session

Poster Display session 3

Presenters

Paul Roepman

Citation

Annals of Oncology (2019) 30 (suppl_5): v574-v584. 10.1093/annonc/mdz257

Authors

P. Roepman1, L. Bosch2, K. Samsom2, L. Schipper3, E. de Bruijn4, L. Hoes3, I. Riethorst1, L. Schoenmaker1, L. van der Kolk5, H. van Snellenberg1, E.E. Voest3, E. Cuppen1, K. Monkhorst2, G. Meijer2

Author affiliations

  • 1 Molecular Diagnostics, Hartwig Medical Foundation, 1098XH - Amsterdam/NL
  • 2 Department Of Pathology, Netherlands Cancer Institute, 1066CX - Amsterdam/NL
  • 3 Department Of Molecular Oncology, Netherlands Cancer Institute, 1066CX - Amsterdam/NL
  • 4 Molecular Diagnostics, Hartwig Medical Foundation, 1066CX - Amsterdam/NL
  • 5 Family Cancer Clinic, Netherlands Cancer Institute, 1066CX - Amsterdam/NL
More

Resources

Abstract 3282

Background

Advances in DNA sequencing technology have strongly reduced costs of Whole Genome Sequencing (WGS) and have made it possible to perform WGS on tumor biopsies within 2 to 3 weeks. Despite its great potential, the value of WGS has so far only been addressed in retrospective or small prospective studies. We have retrospectively shown in > 2,400 metastatic cancer patients that in 31% an approved biomarker for a targeted treatment could be identified. Of these biomarkers, 58% were not targets for standard-of-care (SoC) treatment but suggested off-label use or clinical study eligibility. The potential of WGS in a routine diagnostic setting is explored in the WIDE study and will address feasibility, clinical validity and added value of WGS.

Methods

WGS will be performed on a prospective cohort of 1200 patients with (suspicion of) stage IV metastatic cancer including all solid tumor types. WGS is conducted at the Hartwig Medical Foundation independently of, and in parallel with, SoC diagnostics at the Netherland Cancer Institute. Results are discussed in a tumor board to assess the value of WGS findings for treatment decision and clinical study eligibility. In addition, cost-effectiveness will be evaluated and all participating treating physicians will be asked to what extent WGS has aided their decisions making.

Results

With an accrual rate of 50-75 patients/month starting end of Q2 2019, results of the first 200 patients will be presented. Data from 25 retrospective cases (all with WGS, and 13 with parallel SoC MDx) indicated targets for standard targeted treatment in 5 patients (EGFR, ERBB2 and ROS1 inhibitors) and were identified both WGS and SoC MDx. In 19 patients, WGS found potential clinical study eligibility targets (including PI3K/mTOR, CDK4/6, MEK, FGFR1, MDM2, PARP and checkpoint inhibitors), whereas SoC MDx identified only 6 of these patients as potentially eligible. No relevant DNA aberration was identified for 5 patients.

Conclusions

The WIDE study will provide quantifiable data regarding the feasibility, clinical validity and added value of WGS analysis for patients with metastatic cancer in a routine clinical diagnostic setting.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Netherlands Cancer Institute.

Funding

Illumina.

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings